BiopharmaWatch (@Biopharma_Watch) header
BiopharmaWatch (@Biopharma_Watch) profile picture

FDA/PDUFA Catalyst Calendar | Model Portfolios | Probability of Approval | Options, Earnings, Hedge Fund, and more. https://www.biopharmawatch #biotech #stocks

Boston, MA
Joined December 2023
Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)Photo by BiopharmaWatch (@Biopharma_Watch)
Biotech is not crowded. Two targets are. 19 biotechs are chasing CD19: $LYEL $ADCT $IBRX $CLYM $ALLO $AUTL $CABA $KYTX $FATE $DTIL $TGTX $CRSP $LEGN $XNCR $CGEM $SANA $ARTV $IPSC $NKTX Median value: $0.60B. Only 2 of the 19 have reached Phase 3. We mapped the whole small/mid-cap biotech market. Here is what it looks like ↓
1
5
1,972
AbbVie $ABBV bought Apogee in Q3. That one deal took out $1.13B of VR Adviser's stakes, 34% of its book at the end of Q2. No other of the 43 specialist funds lost as big a share of its book to a takeover.
1
242
VR Adviser Q3 2026 in tickers: Top 10 holdings: $ORKA 17%, $ERAS 14%, $SYRE 11%, $KRSA 7%, $SVRA 5%, $OCUL 4%, $DMRA 4%, $DNTH 4%, $VRDN 3%, $VOR 3% New: $KRSA $ADRX $ARVN $ENTX Exits: $ELVN $HELP $CTMX
1
227
In the quarter Celcuity $CELC won FDA approval, the other 42 specialist funds net sold $469M of it, led by Baker Bros (-$324M) and Avoro (-$199M). Tang went the other way: +$16M, to a $116M stake.
1
267
Tang Q3 2026 in tickers: Top 10 holdings: $AUPH 10%, $CORT 8%, $KNSA 8%, $SYRE 8%, $TARS 7%, $LKFT 5%, $CELC 5%, $MIRM 5%, $PTCT 4%, $IMCR 4% New: $ARDX $VERA $LEGN $SION $SKYE Exits: $CAPR
1
288
📊 The Biotech Tape | Tue Nov 17 A Phase 3 win and a sell-off: SELLAS rose 156%, Cue Biopharma fell 80%. 📈 Up $SLS +156% · Phase 3 REGAL win: 41% lower risk of death in AML $AYTU +46% · To be acquired by Rosemont for $2.70 a share in cash $GLSI +36% · Two abstracts accepted for posters at SABCS 2026 $CING +26% · No new release; rebound after Monday's 13% drop $GANX +26% · Phase 1b rexaceract: Parkinson's motor scores stable at 12 months $MAIA +24% · Phase 2 THIO-101: 88% disease control in 3rd-line NSCLC $INO +16% · No company release $NRXP +14% · Q3 report: launch of its FDA-approved ketamine underway $KROS +13% · New $5M buyback after a $20M milestone payment $RZLT +12% · No new release; rebound after last week's $100M offering 📉 Down $CUE −80% · Sold off after its Q3 update with more Phase 2 CSU data $ENTA −19% · EDP-978 Phase 1 data pushed to 1Q 2027 $RLMD −17% · No new release; second day down after Monday's 14% drop $OMER −17% · Q3 net loss $57.4M incl. $62.0M non-cash derivative loss $LXEO −12% · Gave back Monday's 13% gain on interim LX2020 data $CRBP −11% · Day after its CRB-913 Phase 1b obesity data $FATE −11% · No new release; second straight 11% drop $EPRX −10% · No new release; second straight 10% drop $IDYA −10% · FDA aligned on registrational trials for IDE849 $SMMT −10% · Second day down after the FDA rejected ivonescimab 📅 Tomorrow's FDA decisions and data readouts are on the calendar, link below 👇
1
287
Casdin holds $462M, 20% of its book, in eight stocks that none of the other 42 specialist funds own. The biggest: BioLife Solutions ($175M, since delisted), Illumina $ILMN ($145M) and $LAB ($66M).
1
1
289
Casdin Q3 2026 in tickers: Top 10 holdings: $RVMD 23%, $RLAY 13%, $WGS 12%, BioLife 8%, $ILMN 6%, $GRAL 4%, $TXG 4%, $LAB 3%, $NGNE 2%, $SRRK 2% New: $ORIC $BIIB $EWTX $BNTX $BRVE $RAPP Exits: $SION $IRON
1
205